What are the effects of Mounjaro — and what should you expect?

How does Mounjaro actually produce its effects in the body?

Tirzepatide is described as a dual agonist because it binds to receptors for two gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are naturally released after eating. By activating both pathways at once, Mounjaro signals to the brain that you have eaten, reduces hunger between meals, slows gastric emptying so food stays in your stomach longer, and supports more stable blood-sugar levels. For a fuller breakdown of the mechanism, our page on the effects of tirzepatide on the body's systems goes into each pathway in more detail.

What makes this dual action practically significant is that GIP and GLP-1 receptors are found not only in the gut but in the brain, pancreas and fat tissue. The combined signal appears to produce stronger appetite suppression than either pathway alone, which is reflected in the trial data. SURMOUNT-1, the pivotal phase-3 study published in the New England Journal of Medicine, found average weight reductions of around 20–21% at the 15mg dose over 72 weeks among adults with obesity and no diabetes. Those figures come from a randomised, placebo-controlled trial, not from real-world averages, so individual results will differ. The broader body-level effects of Mounjaro (including its influence on cardiovascular risk markers) are covered separately.

What effects do most people notice in the first few weeks?

Treatment begins at 2.5mg, a dose chosen to give the body time to adjust rather than to produce immediate weight loss. The effects most people notice early on are gastrointestinal: nausea is the most commonly reported, followed by loose stools, constipation, indigestion, burping and a general reduction in appetite. These symptoms tend to be most noticeable in the 24–48 hours after an injection and typically settle as the body adapts, though they often return briefly after each dose increase.

The NHS medicines page for tirzepatide lists the full side-effect profile with guidance on when these are expected and when to seek help. Fatigue and mild headache are also reported by some people, particularly early on. Injection-site reactions (redness or mild irritation at the site) occur in a minority of users and usually resolve quickly. For a specific look at which effects are more troublesome and how to manage them, our page on the less comfortable effects of Mounjaro addresses those in practical terms.

Are there effects of Mounjaro that go beyond appetite and weight?

Yes, and they are worth knowing about before starting. Because tirzepatide slows gastric emptying, oral medicines taken at the same time may be absorbed differently, this is particularly relevant for oral contraceptives. UK guidance advises women using the pill to add a barrier method for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, as absorption of the contraceptive pill may be reduced during that window. If you take other regular medicines, including antidepressants, it is worth checking interactions; our page on Mounjaro and citalopram is one example of how those conversations need to be prescriber-led.

Some people also notice changes in their menstrual cycle, which may relate to shifts in body weight and hormonal balance rather than a direct drug effect, though the evidence is still emerging. There is a dedicated page on Mounjaro's effects on periods for anyone researching that specifically. One serious but infrequent effect to be aware of is acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update highlighting this risk for GLP-1 medicines: severe, persistent stomach pain that may spread to the back, with or without vomiting, requires urgent medical attention. Report any suspected side effects through the MHRA Yellow Card scheme.

How do the effects of Mounjaro compare to what you might have read online?

A lot of what circulates online about tirzepatide's effects mixes genuine trial data with anecdote, and occasionally with information from other countries where dosing presentations or brand names differ. Mounjaro is the UK brand; the US brand name for the same medicine is not available here, and US dosing figures should not be assumed to apply. The effects described in UK clinical guidance and in the licensed prescribing information are the appropriate reference points.

One thing the trial data does confirm is that results vary widely between individuals. Some people experience significant early appetite suppression; others notice the hunger-reduction effect more gradually. The 20–21% average from SURMOUNT-1 includes people across a broad range of responses. For a comparison of how tirzepatide's effects sit alongside semaglutide's, our tirzepatide overview covers the clinical context. And if you are thinking about starting treatment through a regulated UK service, the weight-loss treatment page explains the consultation process, where a prescriber, not software, reviews your answers and health history the same day. That clinical review is how the effects described here become relevant to you specifically.